Lifyorli (relacorilant) — Topline data
Late 2026
We expect results from our trial of relacorilant with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer by the end of this year.Source filing
CORT biotech catalysts & pipeline
CORCEPT THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
Lifyorli (relacorilant) — Regulatory decision
Late 2026
• Marketing Authorization Application (MAA) – European Medicines Agency reviewing MAA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer – Approval expected by the end of this yearSource filing
miricorilant — Topline data
Late 2026
In addition, results from MONARCH, our Phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), are expected by the end of this year.Source filing
Lifyorli (relacorilant) — Regulatory decision
Q4 2026
In October 2025, we submitted a marketing authorization application ("MAA") to the EMA seeking approval in the EU, with an EMA decision expected in the fourth quarter of 2026.Source filing
Lifyorli (relacorilant) — PDUFA
Dec 17
We expect a decision on our NDA by December 17, 2026.Source filing
nenocorilant — Topline data
Late 2027
Our study of nenocorilant with the PD-1 checkpoint inhibitor nivolumab to treat a variety of solid tumors will also produce results by the end of next year,Source filing